Physician profile
Stephan George Dixon
NPI 1396125589
$82,007.82
in general payments reported to CMS, 2019-2025
30 companies · $52K in 2025
The $52K reported for 2025 was more than what 98% of Glaucoma Specialist providers received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $741 · 2020: $325 · 2021: $3,266 · 2022: $4,090 · 2023: $3,223 · 2024: $18K · 2025: $52K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43K · Consulting Fee: $13K · Food and Beverage: $10K · Travel and Lodging: $6,208 · Honoraria: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $42,562.50 |
| Consulting Fee | $13,392.25 |
| Food and Beverage | $10,424.08 |
| Travel and Lodging | $6,207.87 |
| Honoraria | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $34,890.98 | 2019-2025 | Hydrus Microstent, Voyager Dslt, Clareon |
| Abbvie INC. | $20,680.61 | 2022-2025 | Xen Glaucoma Treatment System, Durysta, Lumigan |
| Glaukos Corporation | $13,952.70 | 2020-2025 | Travoprost Intraocular Implant - Idose, Idosetr |
| Alcon Research LLC | $3,267.25 | 2022-2024 | Hydrus Microstent |
| Ivantis, INC | $2,330.68 | 2021 | |
| New World Medical,INC. | $1,971.44 | 2021-2025 | Streamline, Clearpath, Kahook Dual Blade |
| Allergan, INC. | $771.28 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $766.58 | 2019-2025 | Tecnis Iol, Catalys System, Veritas Vision System |
| Sight Sciences, INC. | $503.35 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Carl Zeiss Meditec USA, INC. | $318.70 | 2021-2024 | Quatera 700 |
| Halozyme INC | $304.35 | 2022-2025 | Hylenex Recombinant |
| Ocular Therapeutix, INC. | $268.04 | 2020-2025 | Dextenza |
| Tarsus Pharmaceuticals, INC. | $264.49 | 2024-2025 | Xdemvy |
| Rxsight INC | $259.08 | 2023-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Bausch & Lomb Americas INC. | $223.72 | 2022-2025 | Ic-8 Apthera Iol, Envista Mx60 Iol, Totalvisc |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $179.84 | 2023-2025 | Iyuzeh |
| Harrow Eye, LLC | $168.90 | 2023-2025 | Vevye, Iheezo |
| Eyevance Pharmaceuticals LLC | $152.60 | 2022-2023 | Flarex |
| Dompe US, INC. | $111.65 | 2025 | Oxervate |
| Mallinckrodt Enterprises LLC | $104.38 | 2019 | |
| Aerie Pharmaceuticals, INC. | $95.69 | 2020-2021 | |
| Lensar, INC. | $74.59 | 2024 | Lensar Laser System |
| Regeneron Healthcare Solutions, INC. | $74.47 | 2019 | |
| Amgen INC. | $66.87 | 2024-2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $52.41 | 2021 | |
| Rayner Intraocular Lenses Limited | $41.31 | 2024-2025 | Rayone Emv, Rayone Aspheric, Rayner Cataract Set 1 |
| Horizon Therapeutics Plc | $31.69 | 2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $27.93 | 2025 | |
| Novartis Pharmaceuticals Corporation | $26.54 | 2021-2023 | |
| Biotissue Holdings INC. | $25.70 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephan Dixon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.